• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

RCT Results: Does Relugolix Combined with Estradiol and Progestin Improve Endometriosis Pain While Preserving Bone Mineral Density?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Relugolix is an oral gonadotropin-releasing hormone receptor antagonist
    • Combined with estradiol and a progestin to limit hot flashes and maintain bone mineral density
  • Giudice et al. (The Lancet, 2022) evaluated the efficacy and safety of relugolix combined with estradiol and a progestin for the treatment of endometriosis-related pain

METHODS:

  • Two phase 3, multicenter, randomized, double-blind, placebo-controlled trials
  • Participants
    • Women 18 to 50 years
    • Multicenter: Africa | Australasia | Europe | North America | South America
    • Women had either
      • Surgically or directly visualized endometriosis with or without histological confirmation
      • Endometriosis with histological diagnosis alone
    • Eligible women had
      • Moderate to severe endometriosis-associated pain during the 35-day run-in period
      • Dysmenorrhea Numerical Rating Scale (NRS) score of ≥4.0 on two or more days
      • Mean non-menstrual pelvic pain NRS score of ≥2.5 or a mean score of ≥1.25 that included a score of ≥5 on ≥4 days
  • Interventions
    • Once-daily relugolix combination therapy (relugolix 40 mg, estradiol 1 mg, norethisterone acetate 0.5 mg) for 24 weeks
    • Delayed relugolix combination therapy (relugolix 40 mg monotherapy followed by relugolix combination therapy, each for 12 weeks)
    • Placebo
  • Study design
    • Randomization 1:1:1
    • Efficacy and safety were analyzed in the modified intent-to-treat population
    • Post-treatment follow-up for safety, specifically for bone mineral density and menses recovery, is ongoing at the time of publication
  • Primary outcomes
    • Responder rates at week 24 for dysmenorrhea and non-menstrual pelvic pain

RESULTS:

  • SPIRIT 1: 638 patients | SPIRIT 2: 623 patients
  • Dysmenorrhea responder criteria was significantly improved with combination therapy
    • SPIRIT 1
      • Relugolix combination therapy: 75%
      • Placebo: 27%
      • Treatment difference 47.6% (95% CI, 39.3 to 56.0); p<0.0001
    • SPIRIT 2
      • Relugolix combination therapy: 75%
      • Placebo: 30%
      • Treatment difference 44.9% (95% CI, 36.2 to 53.5); p<0.0001
  • Non-menstrual pain was significantly improved with combination therapy
    • SPIRIT 1
      • Relugolix combination therapy: 58%
      • Placebo: 40%
      • Treatment difference 18.9% (95% CI, 9.5 to 28.2); p<0.0001
    • SPIRIT 2
      • Relugolix combination therapy: 66%
      • Placebo: 43%
      • Treatment difference 23.4% (95% CI, 13.9 to 32.8); p<0.0001
  • Delayed relugolix combination was also associated with pain improvement (p<0.0001 for treatment difference vs placebo)    
    • Dysmenorrhea
      • SPIRIT 1: 72%
      • SPIRIT 3: 73%
    • Non-menstrual pelvic pain
      • SPIRIT 1: 58%
      • SPIRIT 2: 53%
  • Most common adverse events
    • Headache
    • Nasopharyngitis
    • Hot flushes
  • There were nine reports of suicidal ideation across both studies
    • Placebo run-in: 2 reports
    • Placebo: 2
    • Relugolix combination therapy: 2
    • Delayed relugolix combination therapy: 3
  • There were no deaths
  • Bone mineral density loss in the relugolix combination therapy groups was higher than in placebo, but was less than 1% in both studies
    • SPIRIT 1
      • Relugolix combination therapy: –0.70%
      • Delayed relugolix combination: –2.0%
      • Placebo: 0.21%
    • SPIRIT 2
      • Relugolix combination therapy: –0.78%
      • Delayed relugolix combination: –1.9%
      • Placebo: 0.02%
  • Decreases in opioid use were seen in treated patients as compared with placebo

CONCLUSION:

  • Endometriosis-associated pain was significantly improved with relugolix combination therapy
    • The combination therapy was well tolerated, with minimal bone mineral density losses, and mostly minor adverse side effects
  • Combination therapy may allow for long-term treatment that does not rely on opioid use or repeat surgical intervention
  • The authors state

The combination of relugolix, estradiol, and norethisterone acetate might provide the therapeutic benefits of GnRH receptor antagonism to suppress endogenous oestradiol concentrations and improve symptoms of endometriosis while minimising the risk of hypoestrogenic-related bone loss and vasomotor symptoms, potentially enabling long-term use

Learn More – Primary Sources:

Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2)

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

RCT Results: Does Relugolix Combined with Estradiol and Progestin Reduce Fibroid-Associated Heavy Menstrual Bleeding?
RCT Results: Relugolix Versus Leuprorelin for the Management of Endometriosis-Associated Pelvic Pain
Does Elagolix Treatment for Endometriosis Pain Also Reduce Fatigue?
Elaris EM-III and Elaris EM-IV Results: Long-Term Endometriosis Outcomes Following Administration of Elagolix

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site